Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bioatla Inc (BCAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BCAB (1-star) is a SELL. SELL since 5 days. Profits (-24.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.33
1 Year Target Price $8.33
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.47% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.97M USD | Price to earnings Ratio - | 1Y Target Price 8.33 |
Price to earnings Ratio - | 1Y Target Price 8.33 | ||
Volume (30-day avg) 4 | Beta 0.91 | 52 Weeks Range 0.24 - 2.52 | Updated Date 07/5/2025 |
52 Weeks Range 0.24 - 2.52 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -610% |
Management Effectiveness
Return on Assets (TTM) -65.79% | Return on Equity (TTM) -246.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -9837937 | Price to Sales(TTM) 2 |
Enterprise Value -9837937 | Price to Sales(TTM) 2 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA 0.31 | Shares Outstanding 58418100 | Shares Floating 45152550 |
Shares Outstanding 58418100 | Shares Floating 45152550 | ||
Percent Insiders 10.66 | Percent Institutions 32.91 |
Upturn AI SWOT
Bioatla Inc
Company Overview
History and Background
BioAtla, Inc. was founded in 2007 and is a global biotechnology company focused on developing conditionally active antibody therapeutics for cancer treatment. It has evolved from a research-focused organization to a clinical-stage company with a portfolio of innovative therapeutic candidates.
Core Business Areas
- Conditionally Active Biologics (CABs) Development: BioAtla specializes in developing CABs, which are designed to be active in the tumor microenvironment, reducing off-target effects and improving safety.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its CAB candidates in various cancer types.
- Research and Development: BioAtla invests in ongoing research and development to expand its CAB platform and discover new therapeutic targets.
Leadership and Structure
BioAtla is led by a team of experienced biotechnology executives. The organizational structure includes research, development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- BA3011: BA3011 is a CAB-AXL-ADC (antibody-drug conjugate) targeting AXL-expressing tumors. Currently in clinical development. Competitors include companies developing similar ADCs or AXL-targeted therapies, but specific market share data is unavailable due to the developmental stage.
- BA3021: BA3021 is a CAB-ROR2-ADC targeting ROR2-expressing tumors. Currently in clinical development. Competitors include companies developing similar ADCs or ROR2-targeted therapies. No current revenue due to product in clinical trials. Market share unavailable at the current clinical trial phase.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investment in cancer therapeutics. There is a strong demand for novel therapies that can improve patient outcomes while minimizing side effects.
Positioning
BioAtla is positioned as an innovator in the field of conditionally active biologics. Its CAB platform offers a potential competitive advantage by enabling the development of targeted therapies with improved safety profiles.
Total Addressable Market (TAM)
The global oncology market is estimated to be hundreds of billions of dollars. BioAtla is positioned to capture a portion of this market with its targeted cancer therapies, particularly if its CAB platform proves successful in clinical trials. TAM for CAB-based therapies is difficult to quantify precisely but represents a growing segment within the broader oncology market.
Upturn SWOT Analysis
Strengths
- Proprietary CAB technology platform
- Pipeline of novel therapeutic candidates
- Experienced leadership team
Weaknesses
- Dependence on clinical trial outcomes
- Limited commercialized products
- High cash burn rate
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion of CAB platform to new therapeutic areas
- Positive clinical trial results leading to regulatory approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- NKTR
- IMVT
Competitive Landscape
BioAtla's advantage lies in its CAB technology, allowing for more targeted and potentially safer cancer therapies. Disadvantages include dependence on clinical trial outcomes and competition from larger, established companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline advancement and technology development.
Future Projections: Future growth is dependent on clinical trial success and potential commercialization of CAB-based therapies. Analyst estimates are available from various financial data providers.
Recent Initiatives: Recent initiatives include advancing clinical trials, expanding the CAB platform, and seeking partnerships.
Summary
BioAtla is a clinical-stage biotech firm with a novel CAB platform that can potentially yield a more targeted, safer cancer treatment option. Its clinical trial progress is critical, and failure can be detrimental to its stock. The firm's CAB technology and experienced leadership position it well for potential future growth within the oncology sector, but will need to watch out for regulatory hurdles. Partnering with a larger pharmaceutical company may also be a pathway to success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioAtla Investor Relations
- SEC Filings (10-K, 10-Q)
- Market Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioatla Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-12-16 | Co-Founder, CEO & Chairman Dr. Jay M. Short Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.bioatla.com |
Full time employees 61 | Website https://www.bioatla.com | ||
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.